All In Biotech

Drug Trial Radar · NCT00530348

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Nov 24, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 581 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

581

Actual

Start

Aug 2007

Primary completion

Apr 2011

Study completion Apr 2011

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
Collaborators
Bayer
First posted
Sep 17, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to establish the efficacy and safety of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous (SC) interferon beta-1a (Rebif®). The study had enrolled participants who had not previously received MS disease-modifying therapies. Participants had monthly laboratory tests and comprehensive testing every 3 months.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

  • AlemtuzumabBiological

    Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.

  • Interferon beta-1aBiological

    Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Sustained Accumulation of Disability (SAD)Time frame: Up to 2 years
  2. Annualized Relapse RateTime frame: Up to 2 years

Locations

101 sites in 16 countries. Site status is shown where the registry gives one.

  • North Central Neurology Associates, P.C.

    Cullman, Alabama

  • Barrow Neurological Institute, St. Joseph's Hospital & Medical Center

    Phoenix, Arizona

  • Mayo Clinic Arizona

    Scottsdale, Arizona

  • Northwest NeuroSpecialists, PLLC

    Tucson, Arizona

  • Advanced Neurosciences Research

    Fort Collins, Colorado

  • Neurological Associates

    Pompano Beach, Florida

  • Axiom Clinical Research of Florida

    Tampa, Florida

  • Idaho Falls Multiple Sclerosis Center, PLLC

    Idaho Falls, Idaho

  • Consultants in Neurology, Ltd.

    Northbrook, Illinois

  • Fort Wayne Neurological Center

    Fort Wayne, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

  • MidAmerican Neuroscience Institute

    Lenexa, Kansas

  • Associates in Neurology, PSC

    Lexington, Kentucky

  • University of Louisville Research Foundation

    Louisville, Kentucky

  • Louisiana State University Health Sciences Center

    Shreveport, Louisiana

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Wayne State University

    Detroit, Michigan

  • University of Nevada School of Medicine

    Las Vegas, Nevada

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • University of New Mexico, Health Sciences Center, MS Specialty Clinic

    Albuquerque, New Mexico

  • Empire Neurology

    Latham, New York

  • Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates, P.C.

    Patchogue, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Carolinas Medical Center (CMC), Neurosciences & Spine Institute (NSSI)

    Charlotte, North Carolina

  • The Ohio State University Medical Center, Multiple Sclerosis Center

    Columbus, Ohio

  • Oak Clinic for Multiple Sclerosis

    Uniontown, Ohio

  • MS Center of Oklahoma

    Oklahoma City, Oklahoma

  • Lehigh Valley Hospital Neurosciences and Pain Research

    Allentown, Pennsylvania

  • Advanced Neurosciences Institute

    Franklin, Tennessee

  • Biomedical Research Alliance of NY, LLC

    Franklin, Tennessee

  • Hope Neurology PC

    Knoxville, Tennessee

  • Baylor College of Medicine, Maxine Mesinger MS Clinic

    Houston, Texas

  • Central Texas Neurology

    Round Rock, Texas

  • Integra Clinical Research

    San Antonio, Texas

  • Neurology Center of San Antonio

    San Antonio, Texas

  • DIABAID

    Buenos Aires, Argentina

  • Concord Repatriation General Hospital

    Concord, Australia

  • Westmead Hospital

    Westmead, Australia

  • The Wesley Research Institute

    Auchenflower, Queensland, Australia

Showing 40 of 101 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.